La Radiologia medica · 2025
68Ga-DOTATATE PET/CT versus MRI in neuroendocrine liver metastases: a comprehensive per-lesion analysis.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Herold Alexander, Hajati Azadeh, Cao Yihan, Fialkowski Kevin P, Ghosh Soumyadeep, Delaney Francis, Gowda Vrushab, Heidari Pedram, Esfahani Shadi A, Harisinghani Mukesh G, Asmundo Luigi, Beer Lucian, Peña-Trujillo Valeria, Harrington Samantha G, Stufflebeam Steven, Rosen Bruce R, Weber Michael, Huang Susie Y, Catalano Onofrio A
Аннотация
PURPOSE: To evaluate the diagnostic performance of 68Ga-DOTATATE PET, contrast-enhanced CT, combined DOTATATE PET/CT, and MRI in detecting neuroendocrine liver metastases on a per-lesion basis and to assess the added value of diagnostic contrast-enhanced CT to PET interpretation as well as influence of lesion size.
MATERIALS AND METHODS: This retrospective study evaluated patients with histologically-confirmed gastroenteropancreatic neuroendocrine tumors who underwent both contrast-enhanced MRI and 68Ga-DOTATATE PET/CT within 12 weeks between August 2017 and December 2023. Three readers evaluated in consensus MRI, 68Ga-DOTATATE PET, contrast-enhanced CT, and combined PET/CT in separate sessions. Lesions were stratified by size. Diagnostic performance metrics were calculated using generalized estimating equations with reference standard of imaging follow-up or histopathology.
RESULTS: The study included 36 patients (mean age 66.4 ± 10.7 years, 55.6% male) with 720 lesions, of which 582 were metastases. MRI demonstrated superior performance (sensitivity 94.0%, specificity 94.2%) compared to all other modalities (all p < .001). Combined PET/CT showed superior sensitivity (68.1%) compared to PET alone (61.1%) (p < .001). The addition of diagnostic contrast-enhanced CT to PET interpretation identified 41 additional metastases. Size-stratified analysis revealed superior detection of subcentimeter lesions by MRI (sensitivity 83.3% for ≤ 5 mm, 99.6% for 6-10 mm) compared to PET/CT (34.8% and 78.6%, respectively; p < .001). For lesions > 10 mm, both MRI and PET/CT achieved 100% sensitivity, while PET alone reached 94.1% (p = .019).
CONCLUSION: MRI outperforms 68Ga-DOTATATE PET/CT in detecting individual neuroendocrine liver metastases, particularly for subcentimeter lesions. While diagnostic CT improves PET performance, the combination of MRI with 68Ga-DOTATATE PET/CT provides the most comprehensive assessment.
MATERIALS AND METHODS: This retrospective study evaluated patients with histologically-confirmed gastroenteropancreatic neuroendocrine tumors who underwent both contrast-enhanced MRI and 68Ga-DOTATATE PET/CT within 12 weeks between August 2017 and December 2023. Three readers evaluated in consensus MRI, 68Ga-DOTATATE PET, contrast-enhanced CT, and combined PET/CT in separate sessions. Lesions were stratified by size. Diagnostic performance metrics were calculated using generalized estimating equations with reference standard of imaging follow-up or histopathology.
RESULTS: The study included 36 patients (mean age 66.4 ± 10.7 years, 55.6% male) with 720 lesions, of which 582 were metastases. MRI demonstrated superior performance (sensitivity 94.0%, specificity 94.2%) compared to all other modalities (all p < .001). Combined PET/CT showed superior sensitivity (68.1%) compared to PET alone (61.1%) (p < .001). The addition of diagnostic contrast-enhanced CT to PET interpretation identified 41 additional metastases. Size-stratified analysis revealed superior detection of subcentimeter lesions by MRI (sensitivity 83.3% for ≤ 5 mm, 99.6% for 6-10 mm) compared to PET/CT (34.8% and 78.6%, respectively; p < .001). For lesions > 10 mm, both MRI and PET/CT achieved 100% sensitivity, while PET alone reached 94.1% (p = .019).
CONCLUSION: MRI outperforms 68Ga-DOTATATE PET/CT in detecting individual neuroendocrine liver metastases, particularly for subcentimeter lesions. While diagnostic CT improves PET performance, the combination of MRI with 68Ga-DOTATATE PET/CT provides the most comprehensive assessment.
Предметные рубрики MeSH
HumansMaleFemaleLiver NeoplasmsMagnetic Resonance ImagingNeuroendocrine TumorsPositron Emission Tomography Computed TomographyRetrospective StudiesAgedOrganometallic CompoundsMiddle AgedPancreatic NeoplasmsContrast MediaSensitivity and SpecificityRadiopharmaceuticalsIntestinal NeoplasmsGallium RadioisotopesStomach Neoplasms